CELU
CELU
NASDAQ · Biotechnology

Celularity Inc-A

$1.40
+0.02 (+1.45%)
As of Sep 28, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
31.13M
Net Income
-107,551,611
Gross Margin
24.4%
Profit Margin
-345.5%
Rev Growth
+13.9%
D/E Ratio
4.75
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 24.4% 24.4% 53.6% 53.6%
Operating Margin -274.5% -247.1% 20.6% 21.3%
Profit Margin -345.5% -328.2% 22.1% 19.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 31.13M 27.34M 10.25M 10.35M
Gross Profit 7.59M 6.67M 5.50M 5.55M
Operating Income -85,474,102 -67,550,660 2.11M 2.20M
Net Income -107,551,611 -84,998,638 2.27M 1.98M
Gross Margin 24.4% 24.4% 53.6% 53.6%
Operating Margin -274.5% -247.1% 20.6% 21.3%
Profit Margin -345.5% -328.2% 22.1% 19.1%
Rev Growth +13.9% +13.9% +24.9% +1.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 16.74M 16.74M 12.27M 11.63M
Total Equity 3.52M 3.52M 14.31M 15.01M
D/E Ratio 4.75 4.75 0.86 0.77
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -83,723,296 -69,842,932 3.06M 3.48M
Free Cash Flow — — 1.07M 1.08M